Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
7.23
+0.37 (5.39%)
At close: Apr 17, 2025, 4:00 PM
7.38
+0.15 (2.07%)
Pre-market: Apr 21, 2025, 7:04 AM EDT
NTLA's stock price has decreased by -66.85% in the past year and price targets may not have had time to catch up.
Intellia Therapeutics Analyst Ratings
Total Analysts
18
Consensus Rating
Buy
Price Target
$39.44
Upside
+445.50%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +314.94% | Mar 5, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $90 → $50 | Strong Buy | Maintains | $90 → $50 | +591.56% | Mar 4, 2025 |
| Barclays | Barclays | Buy Maintains $55 → $26 | Buy | Maintains | $55 → $26 | +259.61% | Feb 28, 2025 |
| Citigroup | Citigroup | Hold Maintains $12 → $14 | Hold | Maintains | $12 → $14 | +93.64% | Feb 28, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $60 → $50 | Buy | Maintains | $60 → $50 | +591.56% | Feb 28, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $91 → $68 | Strong Buy | Maintains | $91 → $68 | +840.53% | Feb 28, 2025 |
| JP Morgan | JP Morgan | Buy → Hold Downgrades $45 → $13 | Buy → Hold | Downgrades | $45 → $13 | +79.81% | Feb 28, 2025 |
| Morgan Stanley | Morgan Stanley | Buy → Hold Downgrades $56 → $11 | Buy → Hold | Downgrades | $56 → $11 | +52.14% | Jan 27, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $20 → $12 | Hold | Maintains | $20 → $12 | +65.98% | Jan 14, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $60 → $40 | Buy | Maintains | $60 → $40 | +453.25% | Jan 13, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $70 → $60 | Buy | Maintains | $70 → $60 | +729.88% | Jan 10, 2025 |
| BMO Capital | BMO Capital | Buy Maintains $70 → $50 | Buy | Maintains | $70 → $50 | +591.56% | Jan 10, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $90 | Strong Buy | Maintains | $90 | +1,144.81% | Nov 19, 2024 |
| Wells Fargo | Wells Fargo | Buy Maintains $80 → $70 | Buy | Maintains | $80 → $70 | +868.19% | Nov 18, 2024 |
| Wedbush | Wedbush | Hold Reiterates $14 | Hold | Reiterates | $14 | +93.64% | Nov 18, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $88 → $91 | Strong Buy | Maintains | $88 → $91 | +1,158.64% | Nov 18, 2024 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.